Trade Allakos Inc. - ALLK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | N/A |
| Open | N/A |
| 1-Year Change | N/A |
| Day's Range | N/A |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 19, 2025 | 0.2102 | 0.0000 | 0.00% | 0.2102 | 0.2102 | 0.2102 |
| Apr 8, 2025 | 0.2102 | 0.0000 | 0.00% | 0.2102 | 0.2102 | 0.2102 |
| Mar 28, 2025 | 0.2102 | -0.0034 | -1.59% | 0.2136 | 0.2244 | 0.2053 |
| Mar 27, 2025 | 0.2152 | -0.0027 | -1.24% | 0.2179 | 0.2179 | 0.2102 |
| Mar 26, 2025 | 0.2104 | -0.0042 | -1.96% | 0.2146 | 0.2154 | 0.2063 |
| Mar 25, 2025 | 0.2187 | -0.0049 | -2.19% | 0.2236 | 0.2250 | 0.2149 |
| Mar 24, 2025 | 0.2251 | -0.0092 | -3.93% | 0.2343 | 0.2343 | 0.2180 |
| Mar 21, 2025 | 0.2279 | -0.0037 | -1.60% | 0.2316 | 0.2330 | 0.2246 |
| Mar 20, 2025 | 0.2312 | -0.0051 | -2.16% | 0.2363 | 0.2400 | 0.2290 |
| Mar 19, 2025 | 0.2358 | 0.0040 | 1.73% | 0.2318 | 0.2368 | 0.2303 |
| Mar 18, 2025 | 0.2356 | 0.0002 | 0.08% | 0.2354 | 0.2357 | 0.2335 |
| Mar 7, 2025 | 0.2404 | 0.0000 | 0.00% | 0.2404 | 0.2404 | 0.2404 |
| Feb 27, 2025 | 0.2617 | 0.0000 | 0.00% | 0.2617 | 0.2617 | 0.2617 |
| Feb 24, 2025 | 0.2691 | -0.0051 | -1.86% | 0.2742 | 0.2847 | 0.2531 |
| Feb 21, 2025 | 0.2663 | -0.0012 | -0.45% | 0.2675 | 0.2708 | 0.2599 |
| Feb 20, 2025 | 0.2713 | 0.0048 | 1.80% | 0.2665 | 0.2788 | 0.2651 |
| Feb 19, 2025 | 0.2740 | -0.0103 | -3.62% | 0.2843 | 0.2851 | 0.2658 |
| Feb 18, 2025 | 0.2922 | 0.0136 | 4.88% | 0.2786 | 0.3037 | 0.2718 |
| Feb 14, 2025 | 0.2943 | 0.0281 | 10.56% | 0.2662 | 0.2987 | 0.2571 |
| Feb 13, 2025 | 0.2770 | 0.0323 | 13.20% | 0.2447 | 0.2775 | 0.2371 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Allakos Inc. Company profile
About Allakos Inc
Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Allakos Inc revenues was not reported. Net loss increased 76% to $269.9M. Higher net loss reflects Research and Development - Balancing increase of 88% to $176.5M (expense), General and Administrative - Balancing increase of 49% to $44.2M (expense), Stock-based Compensation in SGA increase of 42% to $31M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.10 to -$5.01.
| Industry: | Bio Therapeutic Drugs |
825 Industrial Road
Suite 500
SAN CARLOS
CALIFORNIA 94070
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com